Compare Recursion Pharmaceuticals Inc (RXRX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Exxon Mobil Corporation trades at $167.14 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 323.8× Recursion Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Exxon Mobil Corporation for 99 Days on average.
| RXRX | XOM | |
|---|---|---|
Market Cap | $2.14B | $692.86B |
Volume | 30,789,535 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $6.79 | $171.52 |
52-Week Low | $2.84 | $110.64 |
Typical Hold Time | 22 Days | 99 Days |
Enterprise Value | $1.66B | $724.64B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
ExxonMobil (XOM) trades at $168.56, up 2.48% with strong technical momentum and bullish moving average signals. The company maintains solid profitability with 9.07% net margin and 12.55% ROE, though revenue declined to $323.91B in 2025. Recent news highlights potential Venezuela investment and Guyana/Permian expansion, while analyst consensus shows 36% buy ratings with $168.08 price target.
XOM presents a balanced opportunity with operational strength and strategic growth initiatives, though faces headwinds from declining revenue trends and geopolitical risks. The stock's current valuation at 21.11 P/E appears reasonable given cash flow generation, but investors should monitor execution on production targets and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
